FDA 483 - Genentech, Inc. - March 12, 2024

Genentech, Inc. in South San Francisco, CA, was inspected as a sponsor of investigational drugs, revealing significant deficiencies. The firm failed to maintain adequate records for returned investigational medical products and ensure proper GCP training for decentralized study staff. Additionally, the company was cited for late submission of required safety reports to investigators.